|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
|
|
2
|
Visintin I, Feng Z, Longton G, et al:
Diagnostic markers for early detection of ovarian cancer. Clin
Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suh KS, Park SW, Castro A, et al: Ovarian
cancer biomarkers for molecular biosensors and translational
medicine. Expert Rev Mol Diagn. 10:1069–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bast RC Jr, Urban N, Shridhar V, et al:
Early detection of ovarian cancer: promise and reality. Cancer
Treat Res. 107:61–97. 2002.PubMed/NCBI
|
|
5
|
Jemal A, Thomas A, Murray T and Thun M:
Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002.
View Article : Google Scholar
|
|
6
|
Keyes K, Cox K, Treadway P, et al: An in
vitro tumor model: analysis of angiogenic factor expression after
chemotherapy. Cancer Res. 62:5597–5602. 2002.PubMed/NCBI
|
|
7
|
Keyes KA, Mann L, Cox K, et al:
Circulating angiogenic growth factor levels in mice bearing human
tumors using Luminex Multiplex technology. Cancer Chemother
Pharmacol. 51:321–327. 2003.PubMed/NCBI
|
|
8
|
Sasaroli D, Coukos G and Scholler N:
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are
we there yet? Biomark Med. 3:275–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Szekanecz E, Sandor Z, Antal-Szalmas P, et
al: Increased production of the soluble tumor-associated antigens
CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential
adhesion molecules in synovial inflammation? Ann NY Acad Sci.
1108:359–371. 2007. View Article : Google Scholar
|
|
10
|
Gupta D and Lis CG: Role of CA125 in
predicting ovarian cancer survival - a review of the
epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scholler N and Urban N: CA125 in ovarian
cancer. Biomark Med. 1:513–523. 2007. View Article : Google Scholar
|
|
12
|
Rice LW, Lage JM, Berkowitz RS, et al:
Preoperative serum CA-125 levels in borderline tumors of the ovary.
Gynecol Oncol. 46:226–229. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pearl ML, Yashar CM, Johnston CM, Reynolds
RK and Roberts JA: Exponential regression of CA 125 during salvage
treatment of ovarian cancer with taxol. Gynecol Oncol. 53:339–343.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bast RC Jr, Badgwell D, Lu Z, et al: New
tumor markers: CA125 and beyond. Int J Gynecol Cancer. 15(Suppl 3):
274–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kitawaki J, Ishihara H, Koshiba H, et al:
Usefulness and limits of CA-125 in diagnosis of endometriosis
without associated ovarian endometriomas. Hum Reprod. 20:1999–2003.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye B, Cramer DW, Skates SJ, et al:
Haptoglobin-alpha subunit as potential serum biomarker in ovarian
cancer: identification and characterization using proteomic
profiling and mass spectrometry. Clin Cancer Res. 9:2904–2911.
2003.
|
|
17
|
Raja FA, Hook JM and Ledermann JA:
Biomarkers in the development of anti-angiogenic therapies for
ovarian cancer. Cancer Treat Rev. 38:662–672. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fleige S and Pfaffl MW: RNA integrity and
the effect on the real-time qRT-PCR performance. Mol Aspects Med.
27:126–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park YD, Kim SY, Jang HS, et al: Towards a
proteomic analysis of atopic dermatitis: a
two-dimensional-polyacrylamide gel electrophoresis/mass
spectrometric analysis of cultured patient-derived fibroblasts.
Proteomics. 4:3446–3455. 2004. View Article : Google Scholar
|
|
20
|
Bahk YY, Kim SA, Kim JS, et al: Antigens
secreted from Mycobacterium tuberculosis: identification by
proteomics approach and test for diagnostic marker. Proteomics.
4:3299–3307. 2004.PubMed/NCBI
|
|
21
|
Gobom J, Nordhoff E, Mirgorodskaya E,
Ekman R and Roepstorff P: Sample purification and preparation
technique based on nano-scale reversed-phase columns for the
sensitive analysis of complex peptide mixtures by matrix-assisted
laser desorption/ionization mass spectrometry. J Mass Spectrom.
34:105–116. 1999. View Article : Google Scholar
|
|
22
|
Kim SY, Kim YS and Bahk YY: Proteome
changes induced by expression of tumor suppressor PTEN. Mol Cells.
15:396–405. 2003.PubMed/NCBI
|
|
23
|
Armstrong PB: Proteases and protease
inhibitors: a balance of activities in host-pathogen interaction.
Immunobiology. 211:263–281. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shield-Artin KL, Bailey MJ, Oliva K, et
al: Identification of ovarian cancer-associated proteins in
symptomatic women: A novel method for semi-quantitative plasma
proteomics. Proteomics Clin Appl. 6:170–181. 2012. View Article : Google Scholar
|
|
25
|
Samokyszyn VM, Miller DM, Reif DW and Aust
SD: Inhibition of superoxide and ferritin-dependent lipid
peroxidation by ceruloplasmin. J Biol Chem. 264:21–26.
1989.PubMed/NCBI
|
|
26
|
Healy J and Tipton K: Ceruloplasmin and
what it might do. J Neural Transm. 114:777–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pang WW, Abdul-Rahman PS, Wan-Ibrahim WI
and Hashim OH: Can the acute-phase reactant proteins be used as
cancer biomarkers? Int J Biol Markers. 25:1–11. 2010.PubMed/NCBI
|
|
28
|
Lee CM, Lo HW, Shao RP, et al: Selective
activation of ceruloplasmin promoter in ovarian tumors: potential
use for gene therapy. Cancer Res. 64:1788–1793. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Negishi A, Ono M, Handa Y, et al:
Large-scale quantitative clinical proteomics by label-free liquid
chromatography and mass spectrometry. Cancer Sci. 100:514–519.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choi-Miura NH: Novel human plasma
proteins, IHRP (acute phase protein) and PHBP (serine protease),
which bind to glycosaminoglycans. Curr Med Chem Cardiovasc Hematol
Agents. 2:239–248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Davis AE III, Mejia P and Lu F: Biological
activities of C1 inhibitor. Mol Immunol. 45:4057–4063. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maccio A, Madeddu C, Massa D, et al:
Hemoglobin levels correlate with interleukin-6 levels in patients
with advanced untreated epithelial ovarian cancer: role of
inflammation in cancer-related anemia. Blood. 106:362–367. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Woong-Shick A, Sung-Pil P, Su-Mi B, et al:
Identification of hemoglobin-alpha and -beta subunits as potential
serum biomarkers for the diagnosis and prognosis of ovarian cancer.
Cancer Sci. 96:197–201. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Falco G and Giordano A: pRb2/p130: a
new candidate for retinoblastoma tumor formation. Oncogene.
25:5333–5340. 2006.PubMed/NCBI
|
|
35
|
Schaffer BE, Park KS, Yiu G, et al: Loss
of p130 accelerates tumor development in a mouse model for human
small-cell lung carcinoma. Cancer Res. 70:3877–3883. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ho VM, Schaffer BE, Karnezis AN, Park KS
and Sage J: The retinoblastoma gene Rb and its family member p130
suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene.
28:1393–1399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schweigert FJ and Sehouli J:
Transthyretin, a biomarker for nutritional status and ovarian
cancer. Cancer Res. 65:1114author reply 1114,. 2005.PubMed/NCBI
|
|
38
|
Kozak KR, Su F, Whitelegge JP, Faull K,
Reddy S and Farias-Eisner R: Characterization of serum biomarkers
for detection of early stage ovarian cancer. Proteomics.
5:4589–4596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Min HJ, Bae SM, Kwak SY, et al:
Application of Experion™ assay system for discovery of ovarian
cancer serum biomarkers. Korean J Obstet Gynecol. 50:751–759.
2007.
|
